GSTM1 and anemia (phenotype): As previously mentioned, it has been seen in clinical trials [23, 24, 31, 32] that during the first months of ruxolitinib treatment patients with MF often show an accentuation of the anemia, while later on Hb levels tend to slightly improve or to return to the baseline values.